GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » 3-Year Revenue Growth Rate

Valneva SE (Valneva SE) 3-Year Revenue Growth Rate : -3.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE 3-Year Revenue Growth Rate?

Valneva SE's Revenue per Share for the three months ended in Dec. 2023 was $0.66.

During the past 12 months, Valneva SE's average Revenue per Share Growth Rate was -64.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Valneva SE was 88.40% per year. The lowest was -29.20% per year. And the median was 21.70% per year.

Competitive Comparison of Valneva SE's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Valneva SE's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Valneva SE's 3-Year Revenue Growth Rate falls into.


Valneva SE 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Valneva SE  (NAS:VALN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Valneva SE 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Valneva SE's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:IPH XPAR:AELIS XPAR:ALCLS XPAR:GNFT XPAR:IVA XPAR:TNG XPAR:ADOC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
INRLF:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.